Suppression of IFN-γ expression in Treg cells is dependent on the TCR signaling pathway 2137
Abstract Description Regulatory T cells (Treg) play a key role in immune homeostasis by suppressing excessive immune responses. Treg’s presence in tumors is usually correlated with poor cancer prognosis as it suppresses anti-tumor immune responses. Unlike in effector T cells, the expression of IFN-γ, one of the major cytokines that promote anti-tumor immune response, is suppressed in Treg. The detailed molecular mechanism of this suppression remains unclear. The induction of IFN-γ in Treg will not only tame Treg’s immune suppressive function but also switch Treg into a more pro-inflammatory state to further enhance tumor elimination. Here, we performed a genome-wide CRISPR/Cas9-based screen to identify genes that are involved in the suppression of IFN-γ expression in Tregs. One of the candidate genes from the screen was ZAP70, a component of the TCR signaling pathway. The ablation of ZAP70 and other genes in the TCR pathway led to a significant increase in IFN-γ expression in Tregs while maintaining Foxp3 expression level. Using an adoptive T cell transfer tumor model, we observed a reduction in tumor size in mice transferred with ZAP70-deficient Tregs. Our results suggested that the TCR signaling components in Treg could be potential targets for enhancing anti-tumor immune response. Funding Sources R01-AI1511123 Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
Authors
- Chin San Loo
- Yuqiong Liang (ORCID: https://orcid.org/0009-0007-1242-7115)
- Tien Hua (ORCID: https://orcid.org/0000-0001-6943-3531)
- Ye Zheng (ORCID: https://orcid.org/0000-0003-4587-8100)
Institutions
- Salk Institute for Biological Studies (US)
- Harvard University (US)
Publication Details
- Journal
- The Journal of Immunology
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1093/jimmun/vkaf283.099
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cure Alzheimer's Fund
- Vifor Pharma
- National Institutes of Health